Trials / Unknown
UnknownNCT04622579
Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years
Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 80 Years
- Healthy volunteers
- Not accepted
Summary
About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenalidomide combined with rituximab | lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained. |
Timeline
- Start date
- 2020-10-23
- Primary completion
- 2022-12-31
- Completion
- 2023-03-31
- First posted
- 2020-11-10
- Last updated
- 2020-11-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04622579. Inclusion in this directory is not an endorsement.